Kyverna Therapeutics, Inc.

KYTX Nasdaq CIK: 0001994702

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 5980 HORTON STREET, EMERYVILLE, CA, 94608
Mailing Address 5980 HORTON STREET, EMERYVILLE, CA, 94608
Phone 5106268331
Fiscal Year End 1231
EIN 831365441

Financial Overview

FY2025

$61.55M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
424B5 Prospectus supplement April 2, 2026 View on SEC
S-3 Shelf registration for future offerings March 26, 2026 View on SEC
8-K Current report of material events March 26, 2026 View on SEC
10-K Annual financial report March 26, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
3 Initial insider ownership report March 4, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC

Annual Reports

10-K March 26, 2026
  • Lead therapy KYV-101 targets autoimmune diseases with potential for a one-time cure.
  • Preparing for final-stage trial in Stiff Person Syndrome with FDA approval target in 2026.
View Analysis

Insider Trading

BUY 3 insiders 3 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.